Skip to content

Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD

A Pilot Randomised Controlled Trial to Assess the Feasibility of Cognitive Behavioural Therapy (CBT) Delivered in Time-Intensive and Weekly Treatment Formats for Treatment Resistant Obsessive Compulsive Disorder (OCD).

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02216981
Enrollment
40
Registered
2014-08-15
Start date
2014-08-31
Completion date
Unknown
Last updated
2016-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder (OCD)

Keywords

Obsessive Compulsive Disorder (OCD), Cognitive Behavioural Therapy (CBT), Intensive therapy, Intensive treatment, Treatment Resistant

Brief summary

The purpose of this study is to examine how feasible and acceptable it is to deliver a talking treatment called Cognitive Behavioural Therapy (CBT) in two different formats for people who have had treatment for OCD in the past but it didn't work out for them. The two different treatment formats are CBT delivered on a weekly basis (which is approximately 12-18 hours of therapy delivered weekly for 60-90 minutes each session, followed by 1-3 monthly follow up sessions as needed) and CBT offered in an intensive format (which is having approximately 12-18 hours of therapy all in a 3-week period, followed by 1-3 monthly follow up sessions as needed).

Detailed description

The main aim of this study is to assess the feasibility and acceptability of Intensive CBT for treatment resistant OCD when participants are randomized to this format. This study aims to establish an estimate of the relative efficacy of both Intensive and Weekly CBT when compared individually to wait list, for participants with a diagnosis of OCD, who have previously not responded to CBT.

Interventions

BEHAVIORALCognitive Behavioural Therapy (CBT)

Sponsors

South London and Maudsley NHS Foundation Trust
CollaboratorOTHER
Avon and Wiltshire Mental Health Partnership NHS Trust
CollaboratorOTHER_GOV
University of Bath
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary diagnosis of OCD (as confirmed by the administration of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) (DSM-IV) (SCID-I) . * Participant identifies their main problem as OCD. * Participant has not responded to one or more trials CBT * Yale-Brown Obsessive Compulsive Scale (YBOCS) score of 16 or above. * No change in psychotropic medication (if applicable) for at least 8 weeks prior to study entry. (If such a change has taken place there will be an option for the participant to take part once the medication has been stabilised). * No intention to change psychotropic medication during the course of the trial * Able to speak and read every day English

Exclusion criteria

* Severe psychiatric problem that requires separate treatment at an immediate basis and is linked to risk. * Drug and/or alcohol dependence in last three months * History of Psychosis or Bipolar Disorder

Design outcomes

Primary

MeasureTime frameDescription
Yale- Brown Obsessive Compulsive Scale (Y-BOCS) & Obsessive Compulsive InventoryAssessment, end of treatment (at 3 weeks for Intensive & 12-15 weeks for weekly treatment) and follow up (at 3 & 6 months post treatment completion for both groups).The Y-BOCS is Clinician administered and the OCI is self report, both measures assess the severity of OCD symptoms. These measures will be used to assess change in symptom severity from base line to end of treatment and to assess if there has been a change at end of treatment, if this is maintained at 3 and 6 months following the completion of treatment.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026